Compare IPCA Labs with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs PFIZER - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS PFIZER IPCA LABS/
PFIZER
 
P/E (TTM) x 23.1 33.4 69.0% View Chart
P/BV x 4.5 5.6 79.8% View Chart
Dividend Yield % 0.1 0.6 17.3%  

Financials

 IPCA LABS   PFIZER
EQUITY SHARE DATA
    IPCA LABS
Mar-18
PFIZER
Mar-18
IPCA LABS/
PFIZER
5-Yr Chart
Click to enlarge
High Rs6952,365 29.4%   
Low Rs4001,625 24.6%   
Sales per share (Unadj.) Rs260.2430.3 60.5%  
Earnings per share (Unadj.) Rs19.078.7 24.1%  
Cash flow per share (Unadj.) Rs33.193.2 35.5%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.21.0 18.2%  
Book value per share (Unadj.) Rs213.0586.5 36.3%  
Shares outstanding (eoy) m126.2045.75 275.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.14.6 45.4%   
Avg P/E ratio x28.925.3 113.9%  
P/CF ratio (eoy) x16.621.4 77.4%  
Price / Book Value ratio x2.63.4 75.6%  
Dividend payout %5.325.4 20.7%   
Avg Mkt Cap Rs m69,12091,271 75.7%   
No. of employees `00013.32.6 504.0%   
Total wages/salary Rs m7,3593,143 234.1%   
Avg. sales/employee Rs Th2,477.47,484.8 33.1%   
Avg. wages/employee Rs Th555.21,195.0 46.5%   
Avg. net profit/employee Rs Th180.61,369.1 13.2%   
INCOME DATA
Net Sales Rs m32,83619,685 166.8%  
Other income Rs m4181,143 36.6%   
Total revenues Rs m33,25420,828 159.7%   
Gross profit Rs m4,5055,003 90.0%  
Depreciation Rs m1,777663 268.3%   
Interest Rs m2404 5,719.0%   
Profit before tax Rs m2,9055,479 53.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5111,878 27.2%   
Profit after tax Rs m2,3943,601 66.5%  
Gross profit margin %13.725.4 54.0%  
Effective tax rate %17.634.3 51.3%   
Net profit margin %7.318.3 39.9%  
BALANCE SHEET DATA
Current assets Rs m19,45524,167 80.5%   
Current liabilities Rs m10,0769,544 105.6%   
Net working cap to sales %28.674.3 38.5%  
Current ratio x1.92.5 76.3%  
Inventory Days Days9855 177.7%  
Debtors Days Days6729 233.2%  
Net fixed assets Rs m20,2609,514 213.0%   
Share capital Rs m252458 55.2%   
"Free" reserves Rs m26,63326,375 101.0%   
Net worth Rs m26,88626,832 100.2%   
Long term debt Rs m2,34025 9,360.4%   
Total assets Rs m41,17336,900 111.6%  
Interest coverage x13.11,305.5 1.0%   
Debt to equity ratio x0.10 9,341.7%  
Sales to assets ratio x0.80.5 149.5%   
Return on assets %6.49.8 65.5%  
Return on equity %8.913.4 66.4%  
Return on capital %10.820.4 52.7%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64222 69,830.8%   
Fx outflow Rs m4,8841,489 328.0%   
Net fx Rs m10,759-1,466 -733.7%   
CASH FLOW
From Operations Rs m3,4113,318 102.8%  
From Investments Rs m-1,354-2,383 56.8%  
From Financial Activity Rs m-1,304-1,104 118.2%  
Net Cashflow Rs m753-169 -447.0%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 11.4 7.5 152.0%  
FIIs % 25.3 4.9 516.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 23.7 73.4%  
Shareholders   36,892 85,207 43.3%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   SHASUN PHARMA  WYETH LTD  TORRENT PHARMA  ALEMBIC PHARMA  DIVIS LABORATORIES  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Jumps 1,921 Points, FM's Tax Relief, and Top Cues in Focus Today(Pre-Open)

Share markets in India jumped sharply on Friday after Finance Minister Nirmala Sitharaman announced a slew of measures in her media briefing ahead of the GST Council meet.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

Did the Tax Bonanza Really Deserve a 2,000-point Gain on the Sensex?(Profit Hunter)

Sep 20, 2019

Are investors overdoing their euphoria post the corporate tax cut bonanza?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 20, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - LUPIN COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS